Global Surgical Procedures Volume Market: Gynecology Segment Surging at Robust Rate, finds TMR

The global surgical procedures volume market is dominated by a few players, although they are facing significant competition from local players in respective regional markets. The availability of advanced wound closure material presents a potential threat for the sutures and staples market. However, surgical handheld instruments face major roadblock only from internal substitutes (electrosurgical devices), having no impact on the overall surgical equipment market.

The global surgical procedures volume market was valued at US$1.3 bn in 2014. Expanding at a healthy CAGR of 5.6% during the forecast period of 2015 to 2023, the valuation is estimated to reach US$2.2 bn by the end of 2024.

Vast Population Base makes Asia Pacific Most Profitable Region

On the basis of procedure, the global surgical procedure volume market has been segmented into cardiovascular, orthopedic, neurosurgery, ophthalmic, gynecology, and other procedures, including urology and dental. The ophthalmic procedure segment held the maximum share in the global market in 2014, accounting for US$42.3 bn that year, primarily due to increasing number of ophthalmic surgeries across the globe and the introduction of advanced surgical technologies. However, the gynecology procedure segment is anticipated to grow at a high CAGR of 6.6% during the forecast period. The prominent factors attributed to this growth include a rise in the prevalence of gynecology diseases, changing lifestyle, and surgical up-gradation. The report finds that in 2014, the volume of surgical procedures was 135,986,269, which is anticipated to reach 222,157,438 by 2023.

Read Full Report: http://www.transparencymarketresearch.com/surgical-procedures-volumes-market.html

Geographically, the report studies the regional markets of North America, Europe, Asia Pacific, Latin America, and the Rest of the World. In 2014, Asia Pacific held the maximum market share, at 40.3%, and the region is expected to remain highly prominent during the forecast period. This demand from Asia Pacific is owing to factors such as massive patient base, increasing incidence of cardiovascular diseases, traumatic injuries, neurological disorders, and the introduction of advanced surgical technologies.

Prevalence of Cardiovascular Diseases Driving Demand

Rising geriatric population directly affects the growth and development of cardiac pacemaker products. This is primarily due to the fact that elderly people are highly susceptible to heart diseases such as sick sinus syndrome and atrioventricular blockage. According to the American Heart Association, cardiovascular disease is the leading cause of death globally. Currently, 17.3 million deaths occur per year. A rise in injuries, technological advancements, and rising incidences of cardiovascular, gynecological, neurological, and urological disorders are also seen as factors boosting market growth

Conversely, the rising cost of healthcare as well as complications and infections related to surgical procedures are the factors that may hinder the growth of the global surgical procedures volume market. The shift towards minimally-invasive surgeries is seen as an opportunity in the market.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1289

The author of the report states, “The future of surgery includes making smaller scars, and giving rise to fewer complications. The focus will be on key technologies such as single-incision laparoscopic surgery (SILS).” The author also identifies the development of robotic surgeries for market players to focus on, which is now widely used in operating rooms to perform highly complex and intricate surgeries, with less pain and recovery time.

The information presented in this review is based on a Transparency Market Research report, titled, “Surgical Procedures Volume Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015–2023.”

Biomedical Refrigerators and Freezers Market: Plasma Freezers to Bring New Opportunities in Market Growth, says TMR

The global biomedical refrigerators and freezers market is fragmented in nature and hence display deep competitive rivalry amongst the already established players. This is the main reason why companies in this market are putting in efforts in order to sustain in the market through constant innovation. The leading companies in the market are Eppendorf AG, Thermo Fisher Scientific, Inc., Helmer Scientific, and Panasonic Healthcare Co., Ltd. These companies are leading the market owing to the extensive product range being introduced by them, robust marketing strategies, and their increasing geographic presence, as per Transparency Market Research (TMR).

The global biomedical refrigerators and freezers market is predicted to touch US$4,003.003 mn in 2022. On the basis of type, the segment of plasma freezers is predicted to lead the market over the forecast horizon. The reason for the dominance of this segment includes the rising count of apheresis procedures and the increasing demand to store fresh frozen plasma. In addition, plasma exchange has come up as the most extensively employed apheresis procedures within the U.S. This will raise the adoption of plasma freezers in research laboratories, hospital settings, and blood banks, thus propelling the growth of the overall market. The global plasma freezers market is predicted to touch US$1,195.515 mn in 2022.

Read Full Report: http://www.transparencymarketresearch.com/biomedical-refrigerators-freezers-market.html

Flourishing Medical Tourism Industry to Bring Exponential Market Growth in Asia Pacific

On the basis of end user, the segment of blood banks led the market in the past owing to the rising availability of expensive freezers and refrigerators within blood banks. On the other hand, the segment of research laboratories is predicted to hold the most lucrative opportunity in the market in forthcoming years owing to growing development in life science research in the developing and developed regions. In addition, the increasing support by government for the production of personalized medicines within developed regions will also fuel the growth of this segment.

Geographically, the North America biomedical refrigerators and freezers market emerged as the top market due to the proliferation of R&D institutes, increasing adoption of cutting-edge technologies, and the advanced healthcare infrastructure of this region. On the other hand, the Asia Pacific biomedical refrigerators and freezers market is poised to rise at the swiftest 6.4% CAGR over the forecast period. This is owing to increasing research and development done by the developing economies and the growing industry for medical tourism in the region of Asia Pacific.

Increasing Demand for Organ Transplant and Biopharmaceuticals to Drive Market Growth

There is an increasing occurrence of organ failures globally. Hence, the global biomedical refrigerators and freezers market is predicted to rise due to the rising demand for organ transplant and biopharmaceuticals. In addition, the growing support provided by government on clinical trials and research activities will positively impact the growth of the biomedical refrigerators and freezers market. Furthermore, technological developments have introduced a paradigm shift from the utilization of conventional equipment to developed technology-based equipment offering efficient energy consumption. Thus, the introduction of numerous technological developments in biomedical refrigerators and freezers are expected to bode well for the growth of the market for biomedical refrigerators and freezers.

Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4666

On the other hand, this market is highly fragmented in nature and this may result in lower revenues and higher volumes, thus negatively impacting the development of the market. “The increasing usage of refurbished equipment and huge cost of biomedical refrigerators and freezers may also pull back their demand, thus restraining market growth,” says a TMR analyst.

Nonetheless, the growing focus on commercialization and branding of freezers will bring new growth opportunities in the market, states a TMR analyst.

This information is based on the findings of a report published by Transparency Market Research titled, “Biomedical Refrigerators and Freezers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

New Trends of Synthetic Biology Market with Worldwide Industry Analysis to 2019

A new Transparency Market Research report states that the global synthetic biology market stood at US$1.8 bn in 2012 and is predicted to reach US$13.4 bn by 2019. It is predicted to expand at a whopping CAGR of 32.60% from 2013 to 2019. The title of the report is “Synthetic Biology Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019.” 

Synthetic biology is a synergistic combination of biology and engineering for the construction of artificial biological system in order to gain desired functions (i.e. to reduce cost or improve efficacy). It comprises nascent technologies that enable synthesis of novel biological parts and organisms that are used in the field of healthcare, chemicals, agriculture and others (biosecurity, R&D and energy and environment). The synthetic biology market is witnessing rapid growth owing to increase in demand for renewable fuels and bio-based chemicals and inexpensive drugs and vaccines that utilizes synthetic biology technologies and products. In addition, participation of various organizations such as BioBricks, DIYbio and SynBERC, for the development of synthetic biology field will further augment the growth of this market during the forecast period. However, high cost and strict regulations to use synthetic biology techniques hampers the growth of this market. The global synthetic biology market is estimated to be USD 1,769.8 million in 2012 and is expected to reach USD 13,375.5 million by 2019, growing at a CAGR of 32.6% from 2013 to 2019.

Read Full Press Release: http://www.transparencymarketresearch.com/pressrelease/synthetic-biology-market.htm

Synthetic biology market is segmented mainly by products, by technologies and by applications. Synthetic biology, by product segment is classified as core products and enabling products. Core products are further segmented into synthetic DNA, synthetic genes, synthetic cells, XNA and chassis organisms. The synthetic biology market by core products was dominated by synthetic DNA market in 2012 owing to the commercial availability of this product, compared to other synthetic core products expected to be launched in the market in coming years.

Synthetic biology market, by technologies is segmented as genome engineering, DNA sequencing, bioinformatics and biological components and integrated systems. Genome engineering technology can be used to modify genetic foods, gene cloning and gene therapy. Thus, application of genome engineering increases the scope to utilize this technique and hence accentuates the growth of this market.

Applications of synthetic biology are healthcare, chemicals, agriculture and others. Synthetic biology in healthcare holds largest market share in terms of revenue due to high utilization of synthetic biology techniques to produce cheap drugs and vaccines. Also, commercial availability of synthetic DNA and synthetic genes supports the growth of the healthcare application in the synthetic biology market. Agriculture segment is expected to grow at the highest growth rate during the forecast period.

Interpret a Competitive outlook Analysis Report with free PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=421

Europe contributed the largest share of the global synthetic biology market in 2012 and is expected to grow consistently, owing to increasing efforts of government and private organizations towards the development of this field. North America contributed the second largest share of the total market in 2012. Introduction of novel technologies by will help the growth of this market in North America. The Asia-Pacific region is expected to witness the fastest growth due to support of international organizations (e.g. Biotechnology Industry Organization and others) for the growth of synthetic biology in Asia-Pacific.

In terms of key players, the global synthetic biologymarket is highly fragmented with presence of a large number of players that includeBristol Mayer, Gevo, Inc., Life Technologies, DSM, DuPont, Inc., Genomatica, Inc., LS9, Inc.,Amyris, Inc. and others.

Synthetic Biology Market to Reach US$13.4 bn by 2019 due to Increasing Demand for Enhanced Vaccines and Drugs

Synthetic biology is a synergistic combination of biology and engineering for the construction of artificial biological system in order to gain desired functions (i.e. to reduce cost or improve efficacy). It comprises nascent technologies that enable synthesis of novel biological parts and organisms that are used in the field of healthcare, chemicals, agriculture and others (biosecurity, R&D and energy and environment). The synthetic biology market is witnessing rapid growth owing to increase in demand for renewable fuels and bio-based chemicals and inexpensive drugs and vaccines that utilizes synthetic biology technologies and products. In addition, participation of various organizations such as BioBricks, DIYbio and SynBERC, for the development of synthetic biology field will further augment the growth of this market during the forecast period. However, high cost and strict regulations to use synthetic biology techniques hampers the growth of this market. The global synthetic biology market is estimated to be USD 1,769.8 million in 2012 and is expected to reach USD 13,375.5 million by 2019, growing at a CAGR of 32.6% from 2013 to 2019.

Read Full Press Release: http://www.transparencymarketresearch.com/pressrelease/synthetic-biology-market.htm

Synthetic biology market is segmented mainly by products, by technologies and by applications. Synthetic biology, by product segment is classified as core products and enabling products. Core products are further segmented into synthetic DNA, synthetic genes, synthetic cells, XNA and chassis organisms. The synthetic biology market by core products was dominated by synthetic DNA market in 2012 owing to the commercial availability of this product, compared to other synthetic core products expected to be launched in the market in coming years.

Synthetic biology market, by technologies is segmented as genome engineering, DNA sequencing, bioinformatics and biological components and integrated systems. Genome engineering technology can be used to modify genetic foods, gene cloning and gene therapy. Thus, application of genome engineering increases the scope to utilize this technique and hence accentuates the growth of this market.

Applications of synthetic biology are healthcare, chemicals, agriculture and others. Synthetic biology in healthcare holds largest market share in terms of revenue due to high utilization of synthetic biology techniques to produce cheap drugs and vaccines. Also, commercial availability of synthetic DNA and synthetic genes supports the growth of the healthcare application in the synthetic biology market. Agriculture segment is expected to grow at the highest growth rate during the forecast period.

Interpret a Competitive outlook Analysis Report with free PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=421

Europe contributed the largest share of the global synthetic biology market in 2012 and is expected to grow consistently, owing to increasing efforts of government and private organizations towards the development of this field. North America contributed the second largest share of the total market in 2012. Introduction of novel technologies by will help the growth of this market in North America. The Asia-Pacific region is expected to witness the fastest growth due to support of international organizations (e.g. Biotechnology Industry Organization and others) for the growth of synthetic biology in Asia-Pacific.

In terms of key players, the global synthetic biologymarket is highly fragmented with presence of a large number of players that includeBristol Mayer, Gevo, Inc., Life Technologies, DSM, DuPont, Inc., Genomatica, Inc., LS9, Inc.,Amyris, Inc. and others.

Growing incidence of cancer cases around the globe propels the Small Molecule Kinase Inhibitors Market

Small molecule kinase inhibitors are a form of enzyme inhibitors and are mostly used for the treatment of cancer. Protein kinase aids in the development and progression of tumors and small molecule kinase inhibitors help in obstructing unregulated cell cycle. The growing incidence of cancer cases around the globe is one of the major factors that propel the small molecule kinase inhibitors market. This has driven pharma companies and regulatory bodies to further speed up the process of clinical trials and drug approvals.

The research report analyzing the small molecule kinase inhibitors market studies the industrial landscape and presents a qualitative and quantitative portrait of the expected performance of the market from 2013 to 2019.

The data is derived from primary and secondary research, ensuring absolutely unbiased and authentic evaluation of the small molecule kinase inhibitors market. With the help of Porter’s five forces analysis, the report studies the role of buyers, suppliers, substitutes, new entrants, and competitors in the global market. Growth factors, challenges, and opportunities are identified and discussed at length and added emphasis is laid on government regulations that govern that pharmaceutical industry.

Overview of the small molecule kinase inhibitors market

The small molecule kinase inhibitors market is projected to witness robust growth in the coming years with rising popularity of the next generation of kinase inhibitor drugs, multi-targeted kinase inhibitors, and combination drug therapies. The use of kinase inhibitors for the treatment of various oncology and non-oncology diseases has grown, and while cancer end-use application areas are much stronger, non-cancer therapies are bound to gain interest.

Key kinase inhibitor drugs that have made a significant contribution to the global market include Sorafenib, Gefitinib, Iressa, Temsirolimus, Imatinib, Dasatinib, Rapamycin, Nilotinib, Everolimus, Sunitinib, Erlotinib, and Lapatinib. These commercially-available drugs are designed to target and treat specific diseases. There are numerous small molecule kinase inhibitor drugs in the pipeline, a factor that is anticipated to boost the global market. These pipeline drugs include Pazopanib, Cediranib, CP-690550, Bosutinib, Vandetanib, Alvocidib, Motesanib, and Ridaforolimus.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2110

Despite the availability of a number of kinase inhibitors, the anticipated rise in cancer cases all over the world poses high potential for the growth of the small molecule kinase inhibitors market. However, strict regulatory riders, lengthy approval procedures, and mounting costs of next-generation cancer drugs are matters of concern that hamper the expansion of the small molecule kinase inhibitors market.

Companies mentioned in the research report

Prominent names in the small molecule kinase inhibitors market include Bristol-Myers Squibb, Amgen, KAI Pharmaceuticals, Onyx Pharmaceuticals, Wyeth, OSI Pharmaceuticals, Glaxo SmithKline, Merck & Co, Pfizer, Bayer Schering Pharma, Roche, Sanofi-Aventis, AstraZeneca, Novartis, Genentech, and Celgene Corporation. The research study discusses these companies with respect to company overview, financial standing, product portfolio, recent developments in the small molecule kinase inhibitors market, mergers and acquisitions, business strategies, and SWOT analysis.

Surgical Equipment Market - Worldwide Market Shares, Strategies, and Forecasts 2013 to 2019

According to a market research report published by Transparency Market Research, the global surgical equipment market is estimated to expand at a CAGR of 4.2% during the period between 2013 and 2019. The report, titled “Surgical Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,” projects the global surgical equipment market to be worth US$11.28 bn by 2019. The overall market stood at a valuation of US$8.43 bn in 2013.

Surgical equipment are widely used during surgical procedures for making incisions, grasping certain tissue or skin, holding organs and tissue back, coagulation of blood vessels, providing access to site of operation, and closing the wound by stapling or stitching. Handheld instruments, staples, sutures, and electrosurgical devices are the most commonly used surgical equipment.

The report states that the year-on-year rise in the number of surgical procedures and the growing demand for minimally invasive procedures have fuelled demand from the global surgical equipment market. The rapidly increasing geriatric population and various technical advancements have also augmented the growth of the market.

However, the growing demand for advanced wound closure materials such as hemostats, glues, high-strength medical adhesives, fibrin, and other sealants will negatively impact the market’s growth during the forecast horizon. Additionally, the implementation of the Patient Protection and Affordable Care Act (PPACA) in the U.S. will hamper the growth of the market in North America. There have been a number of incidences of product recalls owing to the side effects associated with some surgical devices. This will also restrain the market. The overall market has a huge scope to grow across the emerging economies in Latin America, Asia Pacific, and Eastern Europe.

In terms of product type, the report broadly segments the global surgical equipment market into surgical sutures and staples, surgical handheld instruments, and electrosurgical devices. The surgical handheld instruments segment has been further divided into forceps, scalpels, retractors, and scissors. The demand for surgical sutures and staples was the highest in 2012 and the segment accounted for over 55% of the market. However, during the forecast period, the segment is expected to lose market share to electrosurgical devices.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=183

The report studies the surgical equipment market across four key regions: North America, Europe, Asia Pacific, and Rest of the World. Presently, the overall market is dominated by Europe and North America. However, growing public investment in the healthcare sector across Latin America and Asia Pacific is expected to fuel the demand for surgical equipment.

The report profiles some of the key players in the global surgical equipment market such as Covidien plc, Ethicon Inc., B. Braun Melsungen AG, Integra LifeSciences Holdings Corporation, CONMED Corporation, CareFusion Corporation, ERBE Elektromedizin GmbH, KLS Martin LP, Medicon eG, Aspen Surgical Products Inc., and Stryker Corporation. It also provides detailed information about the key players including their product portfolio, financial overview, business strategies, and recent developments.

Big Expectations for the future of Surgical Procedures Volume Market

Rising geriatric population across the world has been identified as a major factor fueling the growth of the surgical procedures market. This is primarily due to elderly people are highly susceptible to various chronic disorders. Moreover, growth in the global population over 65 years of age would highly affect market growth. According to the U.S. Census Board, people older than 65 years represented around 13% of the total population; this percentage is expected to reach 20% by 2030. According to the World Health Organization, the global geriatric population is anticipated to reach 1.5 billion by 2050. Countries aging at a rapid pace are the U.S., Japan, and Germany. Other factors driving the surgical procedures volume globally include increasing incidence of chronic disorders and rise in the number of trauma injury cases. The surgical procedures volume market has been segmented into cardiovascular, orthopedic, neurosurgery, ophthalmic, gynecology, and other procedures such as urology and dental.

The cardiovascular procedures segment has been further categorized into cardiac rhythm management devices implantations, interventional cardiology procedures, and heart transplantation. The interventional cardiology procedures sub-segment held the largest share of the cardiovascular procedures segment due to rising usage of cardiac catheterization in structural heart disease and is becoming complex due to increase in incidence of therapeutic catheterization. According to the American Heart Association, over 5 million people in the U.S. are diagnosed with heart valve disease each year, thereby making coronary angiography the leading segment in the interventional cardiology procedures market. The neurosurgery procedures segment has been sub-segmented into craniotomy, aneurysm coil embolization, CSF drainage, and CSF shunts. CSF drainage was the largest sub-segment of the neurosurgery segment, while the craniotomy sub-segment is anticipated to grow at the fastest rate during the forecast period due to recent developments in intraoperative imaging technologies. Orthopedic procedures have been categorized into three segments: joint replacement surgery, ligament/tendon repair surgery, and spine surgery. Joint replacement was the largest sub-segment of the orthopedic procedures segment. The sub-segment is further segmented into knee replacement, hip replacement, and shoulder replacement surgery. Knee replacement surgery dominated the joint replacement surgery segment as it is considered the most effective intervention for severe osteoarthritis, reducing pain and disability, and restoring patients to near normal function. The ophthalmic procedures segment has been categorized into three sub-segments: cataract surgery, refractive surgery, and glaucoma surgery. The cataract surgery sub-segment held the largest share of the global ophthalmic procedures market and in expected to expand at the highest CAGR due to technological advances and better efficacy of the procedures. Gynecology procedures have been categorized into three segments: hysterectomy surgery, uterine artery embolization, and cesarean section surgery. The continued growth of the global gynecology procedures market is attributed to changing lifestyle, increase in per capita income in the emerging markets, and rising prevalence of gynecological diseases such as menorrhagia, uterine fibroids, and cervical cancers globally. The other procedures segment includes urology procedures and dental procedures. The dental procedures sub-segment is anticipated to witness highest growth rate during the forecast period due to technical advancements leading to higher productivity and efficacy.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1289

Asia Pacific dominated the global surgical procedures market in 2014, accounting for a share of over 30% primarily due to large patient base, increasing incidence of cardiovascular diseases, traumatic injuries, neurological disorders, and introduction of advanced surgical technologies. Increase in the geriatric population also plays a major role in the growth of the surgical procedures market. Population over 65 years of age in Asia is likely to increase dramatically by 314%, from 207 million in 2000 to 857 million in 2050. This will increase the number of surgery procedures in the region. North America was the fastest growing market for surgical procedures in terms of volume during the forecast period from 2014 to 2023, due to growing innovation and adoption of new surgical technologies, high growth of minimally invasive surgeries, and C-section surgeries. Moreover, efficient reimbursement facilities, large health care infrastructure, rise in the health care expenditure, and high number of hospital beds per capita are anticipated to accelerate the medical infrastructure development in the U.S. making it the dominating segment in North America. Europe was the second largest market for surgical procedures in terms of volume in 2014, accounting for a share of 31.1% of the global market. Primary factors driving growth in the region include increase in the geriatric population and rise in the incidence of fall injuries, traffic-related injuries, cardiovascular diseases, and orthopedic cases. According to the European Commission database, the average number of surgical procedures for cardiac disorders has increased by around 20% from 2005 to 2010. Germany held the largest share of the surgical procedures market in Europe in 2014 due to the better reimbursement mechanism. Brazil accounted for the largest share of the surgery procedures market in Latin America. Growth of the market is attributed to high prevalence of chronic diseases, rise in geriatric population, and increase in health care expenditure. Mexico is expected to be the fastest growing market in Latin America due to low cost of medical treatments and high prevalence of chronic and infectious diseases.

Amylases Biofuel Enzymes Market - Latest Trends & Insights 2019

Besides the additional cost of fossil fuels, the global amylases biofuel enzymes market is projected to considerably gain from the increasing demand for energy derived from renewable resources. In a new study, titled “Amylases Biofuel Enzymes Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” Transparency Market Research (TMR) presents exhaustive details pertaining to various factors encouraging or inhibiting growth of market.

Overall, the market has been treading along a positive trajectory. However, the high level of carbon emissions from machines deployed at farm plants for biofuels creates bottlenecks for the market. Stringent regulations aimed at curbing carbon emission are therefore expected to hamper the amylases biofuel enzyme producers as well.

Various types of amylase biofuels are currently available in the market, among which cellulosic ethanol is becoming increasingly popular. In addition, scientists have discovered a new enzyme called Caffeoyl shikimate esterase, which is derived from plants. Such discoveries are touted as major breakthroughs in the production of cellulosic biofuels, which are mainly obtained from plastics, chemicals, and crop waste.

Caffeoyl shikimate esterase helps controlling the formation of lignin. Downregulating its functions could reduce 36% lignin per gram of stem materials, which will subsequently boost sugar levels up by four times. The development of this enzyme is therefore expected to prompt a revolution in the amylases biofuel enzymes market.

Regionally, amylases biofuel producers have been witnessing lucrative prospects in Brazil. The country presently leads the global amylases biofuel enzymes market and is expected to continue its dominance through the forecast period between 2013 and 2019. The U.S. has also emerged as an attractive market for amylases biofuel enzymes in the last few years. Ethanol is the most commonly used biofuel additive in the country.

Companies such as Danisco-Genencor and Novozymes have been engaged in the production of enzymes for several years. Together, they account for a dominant share in the production of enzymes. Besides this, Codexis has partnered with Shell to produce enzymes for second generation biofuels. In order to gain a competitive advantage, these companies have been focusing on product development.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2430

While the amylases biofuel enzymes market is still at a nascent stage, increasing investments in research and development by the aforementioned companies will fuel its growth in the forthcoming years. Furthermore, these companies are planning to invest in the development of myriad potential feedstock to scale up their production process. This is expected to drive the market during the forecast period.

Presently, the global amylases biofuel enzymes market is exhibiting a consolidated vendor landscape. Some of the prominent companies operating in the market include Enzyme Supplies Ltd., Enzyme Solutions Inc., aEnzyme Development Corporation, Jiangsu Boli Bioproducts Co. Ltd, Novozymes A/S, Montana Microbial Products, Schaumann Bioenergy, Noor Creations, Specialty Enzymes & Biotechnologies Co., Royal Dsm Nv, and Verenium Corporation

Big Expectations for the future of Opioid Induced Constipation Treatment Market

Transparency Market Research has published a new market report titled, “Opioid Induced Constipation Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023”. According to the report, the global opioid induced constipation treatment market was valued at US$0.4 bn in 2014 and is anticipated to expand at a CAGR of 31.2% from 2015 to 2023 to reach US$4.8 bn by 2023.

The report provides detailed analysis of current and emerging drugs for opioid induced constipation treatment, and the market is estimated based on type of drug class and dosage form of the drugs. Drug classes include mu-opioid receptor antagonist, chloride channel activator, and others based on their mechanism of action. Based on dosage form of drugs, the market has been segmented into solid, semi-solid, and liquid.

The chloride channel activator segment accounted for the largest share of the opioid induced constipation treatment market in 2014 due to first approval and launch of Amitiza in major countries. However, mu-opioid receptor antagonist was the fastest growing segment due to recent launch of the new drug Movantik and presence of pipeline drugs (naldemedine and other early stage drugs). Mu-opioid receptor antagonist drugs target the root cause of constipation by acting on specific peripheral opioid receptors, which revert the opioid action without affecting opioids analgesic action. Presently, Amitiza is the only available drug that belongs to the chloride channel activator class. However, mu-opioid receptor antagonist class consists of Movantik (AstraZeneca), Relistor (Valeant Pharmaceuticals, Inc.), and Naloxone. Additionally, naldemedine is in the late stage clinical trial. The drug is investigational, oral, mu-opioid receptor antagonist and is expected to launch in mid-2016. In August 2015, Shionogi’s naldemedine met primary and secondary endpoints in phase III clinical trial (COMPOSE II) to treat opioid induced constipation. Linaclotide is another potential drug, which is currently in phase II clinical trial. Phase I clinical trial (KODIAK16) is underway to assess the efficacy and safety of naloxegol in the treatment of opioid induced constipation in pediatric patients. The trial is expected to be completed in November 2017. Hence, launch of pipeline drugs during the forecast period is expected to boost the growth the PAMORA segment. The others segment includes Resolor (prucalopride), bulking agents (cellulose and psyllium), stool softeners (docusate), laxatives, and osmotic agents (lactulose, sorbitol, and polyethylene glycol). Major players in this segment are Boehringer Ingelheim GmbH and C.B. Fleet Company, Inc. Traditional laxatives are not legally approved for the treatment of opioid induced constipation. However, low cost of therapy, high awareness, and easy access to medicines accounted significant share of the opioid induced constipation treatment market. For instance, monthly cost of standard laxative therapy ranges from US$ 6 to US$ 80. However, monthly cost of Amitiza ranges from US$ 300 to US$ 400 and from US$ 600 to US$ 1000 for Relistor. Asia Pacific, Latin America, and Middle East & Africa are the major consumers of traditional medicines used to treat opioid induced constipation due to easy access, low cost, and less awareness about targeted therapy.

Furthermore, based on dosage form, the market has been segmented into solid, semi-solid, and liquid. The solid dosage form segment accounted for the largest share of the market in 2014. The segment is expected to maintain its leadership position during the forecast period. This is due to high patient compliance and launch of new drugs in solid form such as capsules, tablets, and pills. The semi-solid and liquid dosage form segments accounted for small shares of the market.

Get Free PDF Brochure for more Professional and Technical industry insights: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6862

The number of players operating in the opioid induced constipation treatment market is small, while demand for the therapy is high. Major players operating in the global opioid induced constipation treatment market are AstraZeneca plc, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., Bayer AG, C.B. Fleet Company, Inc., Boehringer Ingelheim GmbH, Daewoong Co. Ltd., and Cosmo Pharmaceuticals. Acquisitions and collaborations among major companies to commercialize OIC medicines are expected to boost the market during the forecast period. For instance, in March 2015, AstraZeneca and Daiichi Sankyo signed a co-commercialization agreement for Moventik in the U.S. In addition, in October 2014, Takeda and Sucampo entered into global license, development, and commercialization agreement for Amitiza. Hence, strategic agreements between companies are expected to drive the opioid induced constipation treatment market during the forecast period from 2015 to 2023.

Global Membrane Technology Market Boosted by Rise in Pharmaceutical Industry, Poised to Reach US$10.8 bn by 2019

The global membrane technology market is experiencing a significant rise in its valuation. The increasing research and development activities in membrane technology and the growth of several industries such as life sciences, pharmaceutical, and biopharmaceutical in terms of production volume are propelling this market substantially across the world. North America has been leading this market since the last few years. However, Asia Pacific is likely to emerge as the fastest growing membrane technology market across the world.

A research study by Transparency Market Research (TMR) has stated that the worldwide market for membrane technology stood at US$6.4 bn in 2013. Analysts estimate this market to expand at a CAGR of 9.10% between 2014 and 2019 and reach a value of US$10.8 bn by the end of 2019.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1848

What are the key factors driving the global membrane technology market?

The introduction of single-use disposable technology for biopharmaceutical products is the main driving force behind the robust growth of this market. Other than this, the implementation of stringent regulations regarding sterilizing drugs and medications during production is fueling the demand for membrane filtration, adding significantly to the market’s rise.

The continual advances introduced in the membrane technology are also boosting the market for membrane technology considerably across the world.

What are the major challenges faced by this market?

The global membrane technology market faces severe challenges from membrane fouling. In various processes such as membrane bioreactor, solutions or particles get deposited on the surface of the membrane, degrading its performance, thereby hindering the filtration process.

Apart from this, the high capital investment and operational cost associated with membrane technology also restrict companies to venture into this market, impeding its growth.

Browse Research Release:

http://www.transparencymarketresearch.com/pressrelease/global-membrane-technology-market.htm

What are the key strategies adopted by players operating in this for business expansion?

Most of the participants in the global membrane technology market are focusing on research and innovation as well as advancement of existing products to gain competitiveness in the market. One of the leading market players, the US-based GE Healthcare Life Sciences, has recently introduced a new ultrafiltration membrane technology for water treatment, named ZeeWeed 700B to be used in the offshore oil and gas market. This new horizontal-designed, inside-out UF membrane provides removal of solids in oil and gas applications and pre-treatment for seawater used for injection.

In May 2015, the company launched a novel nanofiltration membrane for seawater sulfate removal, specially designed for the upstream oil and gas market.

Mergers, acquisitions, and partnerships have also been popular among market players looking for strengthening their positions by expanding their product portfolios. Advantec MFS, Amazon Filters, Trisep Corp., Novasep, Koch Membrane System, Merck Millipore, 3M Co., and Sartorius are some of the other major enterprises operating in the worldwide membrane technology market.

Demand for Corporate Wellness Programs fueled by Concerns over Employee Wellness

Employers are implementing corporate wellness programs that focus on the improvement of the mental and physical health of their employees. These programs aid organizations in many ways in increasing productivity and reducing attrition rate. A market research report by Transparency Market Research, titled “Corporate Wellness Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023,” focuses on the key trends pertaining to corporate wellness programs at organizational, regional, and global levels.

The report presents a comprehensive overview of the drivers and restraints and their impact on the global corporate wellness market. Government initiatives play a key role in the growth of this market. For instance, in the U.S., the Affordable Care Act with its reform has increased the cap on perks offered to employees for participating in health-related wellness. Also, several governments worldwide have mandated the implementation of wellness programs across medium and large organizations. Moreover, increasing industrialization has also played a vital role in the growth of the global corporate wellness market. The effectivity of these programs in retaining valuable human resource has increased its adoption in large as well as small organizations.

On the flip side, the success of corporate wellness programs depends on active participation of the employees. Currently, inefficient execution of these programs owing to low awareness and lack of participation are acting as key restraint in the growth of the global corporate wellness market. However, the rising adoption of reward-based approach has stirred up the active participation of employees. Moreover, improvements in wellness programs are likely to present notable opportunities to the service providers catering this market.

View exclusive Global strategic Business Report :http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4743

Geographically, the global corporate wellness market is segmented into North America, Asia Pacific, Latin America, Europe, and the Middle East and Africa. The inception of corporate wellness programs in North America and Europe happened many years ago and these are well rooted in these regions. However, Asia Pacific holds immense potential for service providers in the corporate wellness market. Rapid industrialization, increasing governments’ initiatives and improving economic conditions increase the scope for corporate wellness programs in this region.

The report provides insights into the competitive landscape of the global corporate wellness market. It also mentions profiles of the key players including their market share, revenue and cost structure, product specification, capacity, latest development, and contact information. It also offers a list of recommendations for the new market entrants. The key players in the global corporate wellness market are Corporate Wellness Solutions, FitLinxx, GCC Group, Provant Health Solutions, and Trotter Wellness. Also, Fitbit, an activity monitor manufacturer is expanding its business by offering corporate wellness solutions.

Disposable Pain Pumps Market Segment Forecast up to 2019

Pain pumps or intrathecal drug delivery is a method of delivering medication e.g. an opioid directly to the spinal cord. The system incorporates a small pump which is surgically placed under the abdominal skin that delivers medication through a catheter to the area around the spinal cord. Pain pumps are generally advised if all other traditional methods have failed to provide relief from long term symptoms. As the medication is delivered directly to the spinal cord, amount of dose required is much smaller than is needed with oral medication. The pumps are programmed to release small amount of medication over a period of time. These pumps can be programmed to deliver medication at a constant rate as well as in varying amount at different times of the day depending upon patient need and conditions. Once the pump reservoir gets over it can either be refilled with the help of a syringe or can be removed permanently.

Major drivers for disposable pain pump market includes significant pain reduction caused by Failed back surgery syndrome, Reflex sympathetic dystrophy, cancer pain. Ability to perform daily routine activities, low medication of dose, safety and effectiveness and ease of device removal also promotes the adoption for pain pump devices. Recent FDA approvals such as Prometra drug-delivery pump from Flowonix Medical Inc. and SynchroMed(R) II Programmable Pump from Medtronic, Inc. will help in driving demand for pain pumps in coming years. Surgical complications such as infections, side effects, spinal fluid leak leading to headache, occurrence of Inflammatory mass at the tip of the catheter breakdown of device due to failure of critical parts, component or battery are some of the restraining forces for this device market.

Request For PDF: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1825

Geographically North America and Europe market are leading because of trends in clinical practice, guidelines and protocols, reimbursement, regulatory affairs, and the competitive marketplace. Emerging economies of Asia, Middle East and Latin America are predicted to incur the high growth due to growing disease awareness and rising affordability in order to undertake such procedures.

Some of the key players contributing to the disposable pain pumps includes Advanced Infusion, Alaris Medical Systems Inc., Baxter International Inc., Deltec Inc. (Smiths Medical MD, Inc.),I-Flow Corp., McKinley Medical LLLP, Orthofix International, NVSgarlato Laboratories, Sorenson Medical Inc. Stryker Corp.

Global Geriatric Care Services Market's Future Lies in Home Care Services Segment, Expected to Surpass US$850 bn by 2019

The proportion of geriatric population amongst the total population continues to grow and is the single largest driver for the growing global geriatric care services market. Changing family structure in most developed countries has resulted in decrease in time family caregivers can provide. This factor has been crucial in developing and shaping of geriatric care services market. Furthermore, the industrial development and improved job opportunities in the emerging nations of Asia-Pacific have resulted into more people working away from home. This has further led to unavailability of family caregivers which is incentivizing formal care providers. Along with this a large fraction of geriatrics today wish to continue their professional lives but require moderate support from care services. The market in the region has begun developing and returns from geriatric care business in the region are expected to grow in the coming years. The global geriatric care services market was valued at USD 560.4 billion in 2012 and is expected to reach USD 850.0 billion by 2019, growing at a CAGR of 5.9% during the forecast period 2013 to 2019.

The global geriatric care services market is broadly categorized into home care services, adult daycare services, and institutional care services. The institutional care services market constituted the largest segment in the global geriatric care services market while home care services market is expected to witness fastest growth amongst all the segments during the forecast period 2013 to 2019. The freedom to stay at home and cost containment are the prime reasons which explain the emergence of home care services market in the overall geriatric care services market. This segment of market provides unique advantages such as less expensive, desired stay at home and more independence which is helping to gain traction in the steadily growing global geriatric care services market. The shortage of other available options such as nursing homes and assisted living communities in the developing regions is also propelling the growth of global geriatric home care services market.

In 2012, North America was the largest market for geriatric care services contributing to larger proportion of the global market followed by Europe region. These two regions are expected to maintain their leading positions in the global market during the forecast period from 2013 to 2019. Although the market for senior care services in the developed nations of North America and Europe is structured, it is yet in a developing phase. Moreover, the market is absolutely in budding stage in other parts of the world, particularly in countries such as China and India where the situation of elderly care is expected to become grave in the coming years. The market dynamics in China are more rapidly changing relative to India since it has more elderly population while India is still known to be a young country. China will be an attractive destination for the international industry players such as Home Instead Senior Care, Inc., as the government has decided to allow private investments in country’s elderly care services market.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2558

Brookdale Senior Living, Inc., Extendicare, Inc., Genesis HealthCare Corp., Gentiva Health Services, Inc., GGNSC Holdings, Home Instead Senior Care, Inc., Kindred Healthcare, Inc., Senior Care Centers of America, Skilled Healthcare Group, Inc., and Sunrise Senior Living, Inc. are some of the major companies operating in the global geriatric care services market.

Global Biotechnology Market Recovering from Post Recession Crunch, Expected to Reach US$414.5 bn by 2017

According to a recent market research report published by Transparency Market Research, the global biotechnology market is estimated to expand at a CAGR of 11.60% during the period between 2012 and 2017. The report, titled “Global Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2010 - 2017”, projects the global biotechnology market to be worth US$414.5 bn by the end of 2017. The overall market stood at a valuation of US$216.5 bn in 2011.

The report points out that the growing demand for food and limited availability of nonrenewable natural resources will augment the growth of the global biotechnology market. The favorable regulatory scenario governing biotechnology R&D and applications will also boost the market. However, the report mentions that ethical issues associated with clinical trials, coupled with the long research and development lead time, might restrain the growth of the market during the forecast horizon. The global biotechnology market has a huge opportunity to grow with the emergence of biosimilars and increasing application of biotechnology in medical sciences. Cloning, stem cell technology, and nanotechnology are expected to define the future outlook of the market.

In terms of technology, the report segments the global biotechnology market into polymerase chain reaction technology, fermentation technology, tissue engineering and regeneration technology, nanobiotechnology, chromatography, cell-based assay, DNA sequencing technology, and others including fingerprinting and enzyme technology. The demand for nanobiotechnology is projected to rapidly increase in the near future.

On the basis of application, the global biotechnology market is broadly categorized into bioagriculture, biopharmacy, bioindustrial, and bioservices. In 2011, the biopharmaceuticals segment accounted for a 60% share in the market owing to an increase in government funding, widespread technological advancements, and availability of cheap labor in developing economies such as India, China, and Thailand. Increasing demand for food in developing countries is expected to boost the market. Bioseeds offer greater advantages compared to conventional seeds and hence will register exponential growth in demand during the forecast period. This will propel the growth of the bioagriculture segment. By 2018, the segment is projected to reach a valuation of US$27.46 bn.

Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=498

The report studies the global biotechnology market by segmenting it into four key regions: North America, Asia Pacific, Europe, and Rest of the World. North America leads the overall market thanks to the growing focus on renewable chemicals of countries in the region. In 2011, the region accounted for a 42% share in the market.

The report profiles some of the key players in the global biotechnology market such as Amgen Inc., Abbott Laboratories Inc., AstraZeneca plc, Celgene Corporation, Biogen Idec Inc., F. Hoffman La Roche Ltd, Genzyme Corporation, Genentech Inc., Gilead Sciences, Johnson & Johnson, GlaxoSmithKline plc, Pfizer Inc., Lonza Group Ltd., Novartis International AG, Merck & Co. Inc., Novo Nordisk A/S, and Sanofi. Insightful details about the key players, including their financial overview, business strategy, and recent developments, have been included in the report.

Synthetic Biology Market to Reach US$13.4 bn by 2019 due to Increasing Demand for Enhanced Vaccines and Drugs

Synthetic biology is a synergistic combination of biology and engineering for the construction of artificial biological system in order to gain desired functions (i.e. to reduce cost or improve efficacy). It comprises nascent technologies that enable synthesis of novel biological parts and organisms that are used in the field of healthcare, chemicals, agriculture and others (biosecurity, R&D and energy and environment). The synthetic biology market is witnessing rapid growth owing to increase in demand for renewable fuels and bio-based chemicals and inexpensive drugs and vaccines that utilizes synthetic biology technologies and products. In addition, participation of various organizations such as BioBricks, DIYbio and SynBERC, for the development of synthetic biology field will further augment the growth of this market during the forecast period. However, high cost and strict regulations to use synthetic biology techniques hampers the growth of this market. The global synthetic biology market is estimated to be USD 1,769.8 million in 2012 and is expected to reach USD 13,375.5 million by 2019, growing at a CAGR of 32.6% from 2013 to 2019.

Synthetic biology market is segmented mainly by products, by technologies and by applications. Synthetic biology, by product segment is classified as core products and enabling products. Core products are further segmented into synthetic DNA, synthetic genes, synthetic cells, XNA and chassis organisms. The synthetic biology market by core products was dominated by synthetic DNA market in 2012 owing to the commercial availability of this product, compared to other synthetic core products expected to be launched in the market in coming years.

Synthetic biology market, by technologies is segmented as genome engineering, DNA sequencing, bioinformatics and biological components and integrated systems. Genome engineering technology can be used to modify genetic foods, gene cloning and gene therapy. Thus, application of genome engineering increases the scope to utilize this technique and hence accentuates the growth of this market.

Applications of synthetic biology are healthcare, chemicals, agriculture and others. Synthetic biology in healthcare holds largest market share in terms of revenue due to high utilization of synthetic biology techniques to produce cheap drugs and vaccines. Also, commercial availability of synthetic DNA and synthetic genes supports the growth of the healthcare application in the synthetic biology market. Agriculture segment is expected to grow at the highest growth rate during the forecast period.

Interpret a Competitive outlook Analysis Report with free PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=421

Europe contributed the largest share of the global synthetic biology market in 2012 and is expected to grow consistently, owing to increasing efforts of government and private organizations towards the development of this field. North America contributed the second largest share of the total market in 2012. Introduction of novel technologies by will help the growth of this market in North America. The Asia-Pacific region is expected to witness the fastest growth due to support of international organizations (e.g. Biotechnology Industry Organization and others) for the growth of synthetic biology in Asia-Pacific.

In terms of key players, the global synthetic biologymarket is highly fragmented with presence of a large number of players that includeBristol Mayer, Gevo, Inc., Life Technologies, DSM, DuPont, Inc., Genomatica, Inc., LS9, Inc.,Amyris, Inc. and others.

Demand for medical education is primarily driven by the growing preference for online education

The global market for medical education has a handful of players such as Apollo Hospitals, TACT Academy for Clinical Training, Zimmer Biomet Holdings, Inc. (Zimmer Institute), Olympus Corporation, Gundersen Health System, GE Healthcare, and Medical Training College. Transparency Market Research identifies Apollo Hospitals as the leading contributor to the growth of the overall market owing to its extensive course portfolio, strong market penetration in countries in Asia Pacific, and vast scope for practical hospital experience.

“Geographical expansion in several developing countries has been Apollo Hospitals’ leading growth strategy, in addition to the acquisition of smaller local players,” finds the lead author of the TMR study.

In July 2016, Apollo Hospitals Group signed MoUs with Kenyatta National Hospital and Airtel Kenya to not just focus on capacity building in the Kenyan healthcare sector but to also conduct educational lectures and training programs in the country. In the same month, the company signed an agreement with Hainan Ecological Smart City Group in China to develop a highly integrated modern healthcare service facility in the Hainan province, which is likely to lend nursing, medical, and paramedical colleges in the island city tremendous support.

Advantages of Online Training over Traditional Modes of Education a Driving Factor

The demand for medical education is primarily driven by the growing preference for online education. “Online education is a highly lucrative investment avenue,” a TMR analyst observes. “The exposure to modern technologies around the world and the increasing penetration of the internet has greatly fueled the preference of students for online education.” Moreover, online training presents several advantages over traditional modes of education, including variation in training and educational programs, lower cost, comfortable and flexible learning programs, and opportunities for improved technical skills.

In line with this growing trend, TMR predicts that the emergence of e-learning markets in several developing countries will be a major opportunity for players in the medical education market.

High Tuition Fee a Major Roadblock

The cost of higher education, especially in developed countries, continues to pose a key challenge for low-income students. “Medical education is one of the most expensive fields and the tuition fee for classroom courses as well as on-campus training is extremely high. This acts as a major barrier for the medical education market,” the author of the study says.

In addition to this, the declining preference for distance education in medicine and paramedical training is likely to restrict the growth of the medical education market to an extent.

Interpret a Competitive outlook Analysis Report with free PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=517

Steady Growth in Store for Medical Education Market

Expanding at a 4.3% CAGR over the course of the forecast period, the global medical education market is poised to rise from a value of US$25.9 bn in 2015 to US$38.4 bn by 2024. By mode of education, the medical education market is led by on-campus training. Changing student preferences will restrict the demand for distance training by 2024, TMR predicts. However, online training is fast emerging as a lucrative mode of medical education and this segment is likely to register the highest CAGR of 7.29% from 2016 to 2024.

By type of training, the demand for cardiothoracic training has surpassed the rest, while training in radiology presents the highest scope for growth. By geography, North America led the overall medical education market with Asia Pacific as the most rapidly expanding regional segment through the forecast period.

This review is based on the findings of a TMR report titled “Medical Education Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Leber Congenital Amaurosis Market - Competitive Dynamics & Global Outlook 2024

Leber Congenital Amaurosis Market: Overview

Leber congenital amaurosis (LCA) is a disorder of eye mainly affects the retina. Retina is the specific tissue at the back of the eye responsible for detection of light and color. People, primarily babies suffering with this disorder have severe visual impairment from the first year of life. The visual impairment because of this disorder likely to be stable for the rest of the life, whereas is some cases it may worsen very slowly over time. LCA is a congenital disease and usually inherited from the parents where both the parents carry a copy of a recessive gene even though they are normal sighted.

The prime symptom of LCA includes lack of visual reactions and unusual eye movements which collectively termed as nystagmus, where it can be observed within the first few months of life, the other secondary symptoms include glaucoma, cataract and cornea problems. Recently companies got experimental successes regarding treatment of LCA using gene therapy, but research and development work on this therapy is still in the research phase.

Leber Congenital Amaurosis Market: Diagnosis and Treatment Demand Drivers

The disease leber congenital amaurosis is very rare and identified at early stage of the life. According to report published by American Association for Pediatric Ophthalmology and Strabismus, approximately 3 cases per 100,000 births have LCA and out of all congenital blindness or severely reduced vision cases in children only 10% are caused by LCA. According to United States Food and Drug Administration, LCA represents more than 5% of all retinal dystrophies.

All these facts represent demand for the various diagnosis and treatment options for leber congenital amaurosis globally in coming future. The technological advancements in diagnosis of LCA and suitable reimbursement circumstances may drive the growth of the market.

Leber Congenital Amaurosis Market: Diagnosis and Treatment Demand Restraints

On the other hand, high cost involved and limited awareness may hinder the growth of the overall market. Currently there is a gene therapy under clinical trial phase for LCA caused genetic mutation in gene RPE65 whereas the clinical study has been completed by QLT Inc. for LCA Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin: Retinol Acyltransferase (LRAT) Mutations and Nantes University Hospital for genetic study of patients suffering from LCA. According to American Society of Gene and Cell Therapy report in June 2014, Spark Therapeutics is planning to commercialize gene therapies for Leber congenital amaurosis in coning future.

Leber Congenital Amaurosis Market: Segmentation

Leber congenital amaurosis market can be segmented according to different categories such as regional geography and market for diagnosis and treatment. Geographically, this market can be segmented in four regions namely North American, Europe, Asia-Pacific and Rest of the World, out of all these segments North America region will highest contribution in terms of value because of more awareness and higher percentage of total income spent on healthcare compared to other economies.

Followed by this, Europe, Asia-Pacific and Rest of the World respectively could be major segments of the market. It is notable that all the companies which are catering in this segment are based out of either in North America or European region, which represents the one sided growth in these particular countries in the near future.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13307

Leber Congenital Amaurosis Market: Key Players

Currently very few established players in biotechnology market which are on the way to develop gene therapy products for leber congenital amaurosis. Out of these companies, QLT, Inc., ReGenX Biosciences, LLC, Applied Genetic Technologies Corporation, BBB technologies BV and Spark Therapeutics, LLC have upper hand in this market.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.

Increasing Healthcare Expenditure Propels Global Healthcare M2M Market

Assisted Living Requirements Propel Adoption of Healthcare M2M Solutions

The increasing number patients in need of assisted living, where first responder connectivity is critical has become the leading factor supporting the growth of healthcare M2M market. The rising trend of wearable devices amongst the health-conscious people has also spurred a demand for healthcare M2M-based solutions as it allows users to track their fitness levels with just a few clicks. The prominence of Internet of Things (IoT) across all verticals is also expected to boost this market in the coming few years. The biggest advantage of M2M-based healthcare services is anticipated to bring down administrative costs and cut down risks pertaining to diagnoses and treatment, which is propelling the market’s growth.

Transparency Market Research states that these factors are likely to provide an opportunity worth US$10.05 bn by the end of 2023 to the global healthcare M2M market. The market was valued at US$1.56 bn in 2014 and is expected to expand at a CAGR of 22.5% between 2015 and 2023.

Patient-Centric Facilities Give Deployment of M2M Solutions in North America a Boost

Regionally, North America is predicted to be the leading segment in the overall market due to a high acceptance of technology and the increasing expenditure on healthcare. TMR says that the North America healthcare M2M market was valued at US$530.7 mn in 2014. However, by the end of 2023, this market is expected to reach US$3.08 bn, expanding at a CAGR of 20.7% from 2015 and 2023. The growing awareness of the benefits M2M-based healthcare solutions can render has led to an increased deployment of these solutions. The patient-centric attitude of facilities has also led a burgeoning demand for M2M solutions in the recent past. This trend will continue to be persistent in the North America market due to a widening pool of geriatrics and growing cases of chronic diseases.

On the other hand, Asia Pacific is projected to be the fastest-growing segment between 2015 and 2023, at a very high double-digit CAGR of 26.9%. This growth will be a result of increasing M2M connections, especially in countries such as Australia, Japan, and China. Furthermore, the growing support from governments to upgrade the healthcare infrastructure and provide affordable healthcare is also anticipated to boost this market in the Asia Pacific region. The medical facilities segment will be the leading segment in Asia Pacific due to a strong presence of service providers, who are outsourcing telehealth services.

Download Complete Healthcare Analytical Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8590

M2M Healthcare Solutions Gain Traction in Sports and Fitness Applications

The patient well-being application segment is gaining is tremendous importance as hospital staffs across the globe operate under high pressure to provide patient care. The ease of operations brought about by M2M-based healthcare solutions in patient care is a welcome change in this high responsibility job, thereby easing the load on staffers. The decreasing dependency of patients on healthcare professionals has add value to the efficiency of the industry. Furthermore, the sports and fitness application is expected to be the leading segment with a robust CAGR of 26.5% during 2015 and 2023.

The key players in the global healthcare M2M market are Sierra Wireless, Inc., Athenahealth, Inc., GE Healthcare, Apple Inc., Cisco Systems Inc., IBM Corporation, Stanley Healthcare, Allscripts Healthcare Solutions Inc., AT&T Inc., and Gemalto NV. Several players designing and developing cloud-based M2M-healthcare solutions to provide a long-term solution that improves the accessibility to the mammoth volumes of healthcare data.